IRIS
GOZZETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.066
EU - Europa 7.843
AS - Asia 1.431
SA - Sud America 20
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
Totale 20.394
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.028
GB - Regno Unito 2.180
IE - Irlanda 1.685
CN - Cina 1.014
IT - Italia 869
UA - Ucraina 839
SE - Svezia 774
FR - Francia 512
DE - Germania 341
RU - Federazione Russa 300
FI - Finlandia 201
SG - Singapore 167
VN - Vietnam 91
TR - Turchia 62
CA - Canada 30
BE - Belgio 29
IN - India 20
CZ - Repubblica Ceca 19
NL - Olanda 18
JP - Giappone 17
ES - Italia 13
CI - Costa d'Avorio 12
HK - Hong Kong 12
IR - Iran 11
AU - Australia 9
BR - Brasile 9
TW - Taiwan 9
CH - Svizzera 7
EU - Europa 7
RS - Serbia 7
CL - Cile 6
MX - Messico 6
SK - Slovacchia (Repubblica Slovacca) 5
AT - Austria 4
DK - Danimarca 4
EE - Estonia 4
ID - Indonesia 4
LU - Lussemburgo 4
RO - Romania 4
SA - Arabia Saudita 4
TH - Thailandia 4
GR - Grecia 3
KG - Kirghizistan 3
LV - Lettonia 3
MY - Malesia 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
EG - Egitto 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
PT - Portogallo 2
SM - San Marino 2
A1 - Anonimo 1
AR - Argentina 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
HR - Croazia 1
IS - Islanda 1
KR - Corea 1
LT - Lituania 1
MK - Macedonia 1
NG - Nigeria 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
UZ - Uzbekistan 1
Totale 20.394
Salva come PNG Salva come JPEG
Città #
Fairfield 2.035
Southend 1.986
Dublin 1.664
Woodbridge 989
Ashburn 943
Chandler 813
Seattle 772
Houston 766
Wilmington 766
Jacksonville 730
Cambridge 638
Ann Arbor 409
Princeton 372
Siena 306
Nanjing 244
Beijing 222
San Mateo 133
Singapore 112
Boardman 109
San Diego 101
Helsinki 97
Dong Ket 88
Moscow 78
Nanchang 77
Dearborn 63
Shanghai 63
Shenyang 54
Menlo Park 50
Rome 50
Hebei 48
London 48
Florence 47
Izmir 45
New York 42
Tianjin 41
Jiaxing 38
Kunming 35
Milan 32
San Francisco 30
Brussels 29
Norwalk 25
Changsha 22
Kilburn 20
Zhengzhou 18
Brno 17
Ningbo 17
Jinan 16
Fremont 14
Guangzhou 14
Toronto 14
Washington 14
Lappeenranta 13
Abidjan 12
Redwood City 12
Taizhou 12
Bologna 11
Changchun 10
Haikou 10
Hounslow 10
Kocaeli 10
Tokyo 10
Turin 10
Düsseldorf 9
Falls Church 9
Hefei 9
Hong Kong 9
Munich 9
Amsterdam 8
Chiswick 8
Dallas 8
Lanzhou 8
Leawood 8
Pisa 8
Hangzhou 7
Málaga 7
Poggibonsi 7
San Giuliano Terme 7
Taipei 7
Belgrade 6
Colle Di Val D'elsa 6
Fuzhou 6
Livorno 6
Mexico City 6
Zanjan 6
Bratislava 5
Council Bluffs 5
Frankfurt am Main 5
Hyderabad 5
Naples 5
New Bedfont 5
Palermo 5
Philadelphia 5
Phoenix 5
Sacramento 5
Tappahannock 5
Vienna 5
Acton 4
Altopascio 4
Auburn Hills 4
Bangkok 4
Totale 15.716
Salva come PNG Salva come JPEG
Nome #
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 204
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 202
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 199
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 196
Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. 194
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 194
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 191
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 191
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 190
Second generation proteasome inhibitors in multiple myeloma 187
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis 180
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 170
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 167
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 164
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 163
Central nervous system multiple myeloma 160
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients 159
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 156
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 154
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 153
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 150
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 149
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 149
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma. 148
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 146
Evolving treatments in multiple myeloma patients with renal failure 144
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 144
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 143
Predicting the clinical course of Hodgkin lymphoma 143
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 142
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) 141
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice 140
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors 139
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 138
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 138
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 138
Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy 136
Treatment of smoldering multiple myeloma 132
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 131
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study 130
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 129
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 129
Unusual localizations of plasmacytoma 129
Hyperlipidemia in a myeloma patient after bortezomib treatment 128
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 127
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 126
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 126
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 126
Adult lymphoblastic lymphoma: Clinical features and prognostic factors in 53 patients 126
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 124
Extramedullary myeloma relapses 123
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 123
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 122
Central Nervous System Multiple Myeloma 121
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 121
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients 120
FLT3 inhibitors in the management of acute myeloid leukemia 120
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up 119
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 119
Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues 118
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 118
Central nervous system multiple myeloma: a different cytogenetic profile 117
The effects of zoledronic acid on serum lipids in multiple myeloma patients 116
Insights into JAK2-V617F mutation in CML. 114
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 113
Trisomy 13 in a patient with idiopathic myelofibrosis 113
Novel agents in CNS myeloma treatment 113
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 112
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia 111
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma 111
Outcome and toxicity in the modern era of new drugs for multiple myeloma: A reappraisal for comparison with future investigational trials 111
Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports 111
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase II study 111
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: Pathogenetic and prognostic implications 110
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 110
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 109
Efficacy of bortezomib, lenalidomide and dexamethasone(VRD) in secondary plasma cell leukaemia 109
An unusual presentation of chronic B-cell lymphocytic leukaemia 109
Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay 109
Reply to “Rituximab activity in CD20-positive multiple myeloma” 108
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 108
Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission 107
Physicians and end-of-life issues 107
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma 107
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 106
Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders. 105
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia 105
Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization 105
Daratumumab efficacy in extramedullary orbital myeloma 105
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: Thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin 104
IgM myeloma: A multicenter retrospective study of 134 patients 104
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia 103
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 101
Primary plasma cell leukemia: A retrospective multicenter study of 73 patients 101
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients 101
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 101
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 100
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 100
Effect of 5637 conditioned medium (CM) on mitotic index in the cytogenetic evaluation of myeloproliferative disorders 99
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study 99
Totale 13.174
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.046 0 0 277 754 324 402 471 597 408 437 129 247
2020/20214.053 159 392 317 631 247 427 139 547 279 375 257 283
2021/20222.442 160 250 174 179 93 100 125 91 126 285 276 583
2022/20233.273 240 227 440 475 281 677 87 248 298 46 188 66
2023/20242.461 105 57 226 133 68 612 849 48 20 69 39 235
2024/2025469 173 295 1 0 0 0 0 0 0 0 0 0
Totale 20.910